You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
|
|---|---|
| Published in |
Diabetologia, September 2016
|
| DOI | 10.1007/s00125-016-4101-6 |
| Pubmed ID | |
| Authors |
Huilin Tang, Xi Zhang, Jingjing Zhang, Yufeng Li, Liana C. Del Gobbo, Suodi Zhai, Yiqing Song |
| Abstract |
By analysing available evidence from randomised controlled trials (RCTs), we aimed to examine whether and to what extent sodium-glucose cotransporter 2 (SGLT2) inhibitors affect serum electrolyte levels in type 2 diabetes patients. We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov up to 24 May 2016 for published RCTs of SGLT2 inhibitors that reported changes in serum electrolyte levels. Weighted mean differences (WMD) between each SGLT2 inhibitor and placebo were calculated using a random-effects model. Dose-dependent relationships for each SGLT2 inhibitor were evaluated using meta-regression analysis. Eighteen eligible RCTs, including 15,309 patients and four SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin and ipragliflozin) were evaluated. In patients without chronic kidney disease, each SGLT2 inhibitor significantly increased serum magnesium levels compared with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg). Canagliflozin increased serum magnesium in a linear dose-dependent manner (p = 0.10). Serum phosphate was significantly increased by dapagliflozin. Serum sodium appeared to significantly differ by SGLT2 inhibitor type. No significant changes in serum calcium and potassium were observed. Findings were robust after including trials involving patients with chronic kidney disease. SGLT2 inhibitors marginally increased serum magnesium levels in type 2 diabetes patients indicating a drug class effect. Further investigations are required to examine the clinical significance of elevated magnesium levels in individuals with type 2 diabetes. |
X Demographics
The data shown below were collected from the profiles of 43 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 11 | 26% |
| Japan | 6 | 14% |
| India | 2 | 5% |
| Chile | 1 | 2% |
| United Kingdom | 1 | 2% |
| Venezuela, Bolivarian Republic of | 1 | 2% |
| Saudi Arabia | 1 | 2% |
| Unknown | 20 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 39 | 91% |
| Practitioners (doctors, other healthcare professionals) | 3 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Russia | 1 | 1% |
| Unknown | 94 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 15% |
| Student > Ph. D. Student | 13 | 14% |
| Student > Bachelor | 10 | 11% |
| Student > Master | 8 | 8% |
| Other | 6 | 6% |
| Other | 16 | 17% |
| Unknown | 28 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 48% |
| Agricultural and Biological Sciences | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Nursing and Health Professions | 2 | 2% |
| Other | 8 | 8% |
| Unknown | 27 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2023.
All research outputs
#1,113,194
of 25,732,188 outputs
Outputs from Diabetologia
#576
of 5,376 outputs
Outputs of similar age
#19,769
of 330,705 outputs
Outputs of similar age from Diabetologia
#15
of 80 outputs
Altmetric has tracked 25,732,188 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,376 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.7. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,705 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.